Senolytics Plus TB Drugs Boost Survival in Infected Mice
Graded Preliminary — mouse study in young, aged and susceptible strains testing senolytics with TB therapy, yet the benefit is limited to animals and has not been tested in people.
This study suggests senolytic drugs may warrant testing as add-on therapy for tuberculosis in humans.
Tuberculosis triggers some lung cells to become senescent (zombie-like cells that won't die but cause damage). Researchers gave infected mice a senolytic cocktail of dasatinib, quercetin, and fisetin alongside standard TB treatment. The combo improved survival and reduced lung damage, especially in older mice.
Disclaimer: Research summaries are provided for informational purposes only and do not constitute medical advice. Always consult a qualified healthcare professional before making changes to your health routine.